Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder

被引:19
作者
Thakrar, Ashish P. [1 ,2 ]
Uritsky, Tanya J. [2 ,3 ]
Christopher, Cara [3 ]
Winston, Anna [4 ]
Ronning, Kaitlin [5 ]
Sigueza, Anna Lee [5 ]
Caputo, Anne [5 ]
McFadden, Rachel [2 ,7 ]
Olenik, Jennifer M. [4 ]
Perrone, Jeanmarie [2 ,6 ]
Delgado, M. Kit [2 ,6 ]
Lowenstein, Margaret [2 ,4 ]
Compton, Peggy [2 ,7 ]
机构
[1] Univ Penn, Corporal Michael J Crescenz Vet Affairs Med Ctr, Natl Clinician Scholars Program, Philadelphia, PA 19104 USA
[2] Univ Penn, Ctr Addict Med & Policy, Philadelphia, PA 19104 USA
[3] Hosp Univ Penn, Dept Pharm, Philadelphia, PA USA
[4] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[5] Univ Penn, Sch Nursing, Philadelphia, PA USA
[6] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA USA
[7] Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA USA
关键词
Opioid use disorder; Hospitalized patients; Fentanyl; Opioid agonist treatment; Short-acting opioids; Methadone; Buprenorphine; Opioid withdrawal; MEDICAL ADVICE; PEOPLE; EXPERIENCES; MORTALITY; SEDATION; SCALE; DRUGS; RISK; CARE; PAIN;
D O I
10.1186/s13722-023-00368-z
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundPatients with opioid use disorder (OUD) frequently leave the hospital as patient directed discharges (PDDs) because of untreated withdrawal and pain. Short-acting opioids can complement methadone, buprenorphine, and non-opioid adjuvants for withdrawal and pain, however little evidence exists for this approach. We described the safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with OUD at an academic hospital in Philadelphia, PA.MethodsFrom August 2021 to March 2022, a pharmacist guided implementation of a pilot sOAT protocol consisting of escalating doses of oxycodone or oral hydromorphone scheduled every four hours, intravenous hydromorphone as needed, and non-opioid adjuvants for withdrawal and pain. All patients were encouraged to start methadone or buprenorphine treatment for OUD. We abstracted data from the electronic health record into a secure platform. The primary outcome was safety: administration of naloxone, over-sedation, or a fall. Secondary outcomes were PDDs and respective length of stay (LOS), discharges on methadone or buprenorphine, and discharges with naloxone. We compared secondary outcomes to hospitalizations in the 12 months prior to the index hospitalization among the same cohort.ResultsOf the 23 cases, 13 (56.5%) were female, 19 (82.6%) were 40 years or younger, and 22 (95.7%) identified as White. Twenty-one (91.3%) regularly injected opioids and four (17.3%) were enrolled in methadone or buprenorphine prior to hospitalization. sOAT was administered at median doses of 200-320 morphine milligram equivalents per 24-h period. Naloxone administration was documented once in the operating room, over-sedation was documented once after unsanctioned opioid use, and there were no falls. The PDD rate was 44% with median LOS 5 days (compared to PDD rate 69% with median LOS 3 days for prior admissions), 65% of sOAT cases were discharged on buprenorphine or methadone (compared to 33% for prior admissions), and 65% of sOAT cases were discharged with naloxone (compared to 19% for prior admissions).ConclusionsPilot implementation of sOAT was safe. Compared to prior admissions in the same cohort, the PDD rate was lower, LOS for PDDs was longer, and more patients were discharged on buprenorphine or methadone and with naloxone, however efficacy for these secondary outcomes remains to be established.
引用
收藏
页数:9
相关论文
共 42 条
[2]   Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association [J].
Baddour, Larry M. ;
Weimer, Melissa B. ;
Wurcel, Alysse G. ;
McElhinney, Doff B. ;
Marks, Laura R. ;
Fanucchi, Laura C. ;
Garrigos, Zerelda Esquer ;
Pettersson, Gosta B. ;
DeSimone, Daniel C. .
CIRCULATION, 2022, 146 (14) :E187-E201
[3]  
Bettigole C, HLTH ALERT RISKS XYL
[4]  
Bettigole Cheryl, 2020, PHILADELPHIA DEP PUB
[5]   Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series [J].
Brar, Rupinder ;
Fairbairn, Nadia ;
Colizza, Kate ;
Ryan, Andrea ;
Nolan, Seonaid .
JOURNAL OF ADDICTION MEDICINE, 2021, 15 (02) :163-166
[6]   Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines [J].
Calcaterra, Susan L. ;
Bottner, Richard ;
Martin, Marlene ;
Englander, Honora ;
Weinstein, Zoe M. ;
Weimer, Melissa B. ;
Lambert, Eugene ;
Ronan, Matthew V. ;
Huerta, Sergio ;
Zaman, Tauheed ;
Ullal, Monish ;
Peterkin, Alyssa F. ;
Torres-Lockhart, Kristine ;
Buresh, Megan ;
O'Brien, Meghan T. ;
Snyder, Hannah ;
Herzig, Shoshana J. .
JOURNAL OF HOSPITAL MEDICINE, 2022, 17 (09) :679-692
[7]   Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach [J].
Cohen, Shawn M. ;
Weimer, Melissa B. ;
Levander, Ximena A. ;
Peckham, Alyssa M. ;
Tetrault, Jeanette M. ;
Morford, Kenneth L. .
JOURNAL OF ADDICTION MEDICINE, 2022, 16 (04) :399-406
[8]   In-Hospital Illicit Drug Use and Patient-Directed Discharge: Barriers to Care for Patients With Injection-Related Infections [J].
Eaton, Ellen F. ;
Westfall, Andrew O. ;
McClesky, Brandi ;
Paddock, Cayce S. ;
Lane, Peter S. ;
Cropsey, Karen L. ;
Lee, Rachael A. .
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (03)
[9]   Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report [J].
Ehrman-Dupre, Rachel ;
Kaigh, Caroline ;
Salzman, Matt ;
Haroz, Rachel ;
Peterson, Lars-Kristofer ;
Schmidt, Ryan .
JOURNAL OF ADDICTION MEDICINE, 2022, 16 (05) :595-598
[10]   Hospital Standards of Care for People with Substance Use Disorder [J].
Englander, Honora ;
Davis, Corey S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (08) :672-675